Assembly Biosciences, Inc. Operating Lease, Payments
Assembly Biosciences, Inc. (ASMB) reported Operating Lease, Payments of $3.67 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-22.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2023-03-22
- Assembly Biosciences, Inc. operating lease, payments for the quarter ending 2021-12-31 was $930.00K, a 17.77% decline year-over-year.
- Assembly Biosciences, Inc. operating lease, payments for the quarter ending 2021-09-30 was $912.00K, a 19.65% decline year-over-year.
- Assembly Biosciences, Inc. operating lease, payments for the quarter ending 2021-06-30 was $903.00K, a 19.88% decline year-over-year.
- Assembly Biosciences, Inc. operating lease, payments for the quarter ending 2021-03-31 was $1.04M, a 7.05% decline year-over-year.
- Assembly Biosciences, Inc. operating lease, payments for fiscal 2022 was $3.67M, a 3.06% decline from fiscal 2021.
- Assembly Biosciences, Inc. operating lease, payments for fiscal 2021 was $3.79M, a 16.11% decline from fiscal 2020.
- Assembly Biosciences, Inc. operating lease, payments for fiscal 2020 was $4.51M, a 5.72% increase from fiscal 2019.
- Assembly Biosciences, Inc. operating lease, payments for fiscal 2019 was $4.27M.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $3.67M 10-K · filed 2023-03-22 | ||||
| 2021-12-31 | $930.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $1.84M derived: sum of 2 quarters · filed 2023-03-22 | $2.75M derived: sum of 3 quarters · filed 2023-03-22 | $3.79M 10-K · filed 2023-03-22 | |
| 2021-09-30 | $912.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.81M derived: sum of 2 quarters · filed 2021-11-04 | $2.86M 10-Q · filed 2021-11-04 | $3.99M derived: sum of 4 quarters · filed 2022-03-11 | |
| 2021-06-30 | $903.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.94M 10-Q · filed 2021-08-05 | $3.08M derived: sum of 3 quarters · filed 2022-03-11 | $4.21M derived: sum of 4 quarters · filed 2022-03-11 | |
| 2021-03-31 | $1.04M 10-Q · filed 2021-05-06 | $2.17M derived: sum of 2 quarters · filed 2022-03-11 | $3.31M derived: sum of 3 quarters · filed 2022-03-11 | $4.43M derived: sum of 4 quarters · filed 2022-03-11 | |
| 2020-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $2.27M derived: sum of 2 quarters · filed 2022-03-11 | $3.39M derived: sum of 3 quarters · filed 2022-03-11 | $4.51M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $2.26M derived: sum of 2 quarters · filed 2021-11-04 | $3.38M 10-Q · filed 2021-11-04 | $4.46M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $2.25M 10-Q · filed 2021-08-05 | $3.33M derived: sum of 3 quarters · filed 2021-08-05 | $4.42M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | $1.12M 10-Q · filed 2021-05-06 | $2.20M derived: sum of 2 quarters · filed 2021-05-06 | $3.29M derived: sum of 3 quarters · filed 2021-05-06 | $4.35M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2019-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.17M derived: sum of 2 quarters · filed 2021-02-25 | $3.23M derived: sum of 3 quarters · filed 2021-02-25 | $4.27M 10-K · filed 2021-02-25 | $4.27M 10-K · filed 2020-03-04 |
| 2019-09-30 | $1.09M 10-Q · filed 2019-11-07 | $2.15M derived: sum of 2 quarters · filed 2019-11-07 | $3.19M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $1.06M 10-Q · filed 2019-08-05 | $2.10M 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | $1.04M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |